GlassScriptPhysician profile
Paul Shiu
NPI 1508495433
$2,507.56
in general payments reported to CMS, 2019-2025
20 companies · $2,508 in 2025
The $2,508 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,408.56 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $461.80 | 2025 | Tavneos, Evenity, Prolia |
| Janssen Biotech, INC. | $318.58 | 2025 | Tremfya |
| Abbvie INC. | $288.42 | 2025 | |
| Novartis Pharmaceuticals Corporation | $232.82 | 2025 | |
| Aurinia Pharma U.S., INC. | $189.53 | 2025 | Lupkynis |
| Ucb, INC. | $175.17 | 2025 | Bimzelx |
| Organon LLC | $124.77 | 2025 | Hadlima, Renflexis |
| E.R. Squibb & Sons, L.L.C. | $86.21 | 2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $83.59 | 2025 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $72.53 | 2025 | Saphnelo |
| Pfizer INC. | $68.82 | 2025 | |
| Sobi, INC | $65.85 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $62.72 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.05 | 2025 | Ofev, Jascayd |
| Genzyme Corporation | $56.83 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $47.97 | 2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $46.30 | 2025 | Taltz |
| Depuy Synthes Sales INC. | $27.12 | 2025 | Monovisc |
| Glaxosmithkline, LLC. | $19.98 | 2025 | Benlysta |
| Pacira Pharmaceuticals Incorporated | $16.50 | 2025 | Zilretta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Shiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.